Arcera’s sovereign-backed ambition to build a global life sciences bridge

Established by ADQ, an active sovereign investor focused on critical infrastructure and global supply chains, Arcera is redefining what it means to build a global healthcare company from the region. In an industry often shaped by short-term market cycles, Arcera combines the independence of a privately held company with the scale and ambition of a global player, backed by a clear mandate to expand into new markets and strengthen healthcare resilience. For Rafael Ferrer, senior vice president corporate development, that difference is more than structural. It defines how Arcera approaches growth. Talking to The Pharma Letter, he explains: “We’re not really constrained by the quarterlies. We’re able to really think about longer-term bets in terms of how we build a vision and how we build partnerships.”

“We’re not really constrained by the quarterlies. We’re able to really think about longer-term bets in terms of how we build a vision and how we build partnerships.”

In addition to its long-term focus, the group is defined by its breadth of vision. Created in 2024, Arcera integrated Swiss pharmaceutical player Acino, Egyptian manufacturer Amoun and Turkey’s contract manufacturer Birgi Mefar Group under one umbrella. With more than 2,000 branded medicines, over 6,000 employees and operations in over 60 countries, the group now has a sizable footprint reaching patients in more than 120 markets. Its focus is high-growth markets, where it claims leadership positions in the Middle East, South Africa, Latin America and Ukraine. Yet, integration of these legacy businesses gives it more than geographic reach.

Summary: Arcera consolidates regional strengths into a global platform, leveraging sovereign backing to pursue long-term healthcare investments and market expansion across diverse regions while maintaining a cohesive, integrated portfolio.

The Pharma Letter — 2025-11-17

More News